294results about "Carbohydrate active ingredients" patented technology

Provided are compounds of Formula I:nucleosides, nucleoside phosphates and prodrugs thereof, wherein R6 is CN, ethenyl, 2-haloethen-1-yl, or (C2-C8)-alkyn-1-yl. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections.

Described herein are methods of for treating and / or preventing Major adverse cardiovascular events (MACE). by administering to a subject in need thereof, a combination of a sodium-glucose transport protein 2 (SGLT2) inhibitor and a compound of Formula I or a stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof, wherein the variables of Formula I are as defined herein.

The present application relates to a synbiotic composition for use in the amelioration, treatment, reductions of symptoms of a neuropsychiatric disorder and / or the reduction of side effects of a pharmacological treatment of a neuropsychiatric disorder, wherein the synbiotic composition comprises at least two bacterial strains chosen from the group consisting of Lactobacillus plantarum, Lactobacillus paracasei, Pediococcus pentosaceus, Leuconostoc mesenteroides, and Bifidobacterium breve; and at least one dietary fibers chosen from the group consisting of inulin, pectin, beta-glucan, resistant starch, a galacto-oligosaccharide, an isomalto-oligosaccharide and a rice fiber.

The present disclosure relates to the endothelin receptor antagonist (ERA) zibotentan in combination with the sodium-dependent glucose cotransporter 2 (SGLT-2) inhibitor dapagliflozin for use in the treatment of certain endothelin related diseases.

Disclosed is a process for the synthesis of mono- and bis-nitrosylated propanediols, as well as compositions and pharmaceutical formulations that includes the compounds. The process proceeds by reacting a corresponding propanediol that is not nitrosylated with a source of nitrite, optionally in the presence of a suitable acid. When the source of nitrite is an organic nitrite, reacting step is performed in a suitable organic solvent, and when the source of nitrite is an inorganic nitrite, the reacting step is performed in a bi-phasic solvent mixture comprising an aqueous phase and a non-aqueous phase. Also disclosed are methods of treating a condition wherein administration of nitric oxide (NO) has a beneficial effect by administering said compounds, compositions or formulations.

Provided are methods for treating cancer using local administration of certain CpG oligonucleotides (CpG ODN) and systemic administration of a checkpoint inhibitor such as an anti-PD-1 antibody, an anti-PD-L1 antibody, and / or an anti-CTLA-4 antibody. In preferred embodiments, the CpG ODN are selected based on their propensity to induce high amounts of interferon alpha (IFN-α) and T-cell activation relative to interleukin-10 (IL-10) and B-cell activation. In certain embodiments, the methods further include pretreatment with radiotherapy, to potentiate the combination immunotherapy.

The present invention relates to sulforaphane glycoconjugate compounds, as well as to the synthesis and therapeutic uses thereof for treating inflammatory diseases.

Provided are a composite tablet comprising a first layer containing dry granules containing sitagliptin, or a pharmaceutically acceptable salt thereof, or a hydrate thereof, and dapagliflozin, or a pharmaceutically acceptable salt thereof, or a hydrate thereof, and a second layer containing wet granules containing metformin, or a pharmaceutically acceptable salt thereof, and colloidal silicon dioxide, and a method for producing the same.

The present invention relates to modulators of TNF signalling for use in treating and / or preventing acute pain. In particular, a modulator of TNF signalling may be a tumour necrosis factor receptor 2 (TNFR2) agonist comprising (i) a TNFR2 binding domain comprising three TNF homology domains (THD) that specifically bind to TNFR2; and (ii) an Fc domain. The present invention further relates to combinations of a TNFR2 agonist and an inhibitor of tumour necrosis factor receptor 1 (TNFR1) signalling.

The present invention relates to the use of one or more SGLT-2 inhibitors or pharmaceutically acceptable forms thereof in combination with pimobendan and / or telmisartan or pharmaceutically acceptable forms thereof for the prevention and / or treatment of one or more heart diseases in non-human mammals / non-human mammalian animals, such as dogs or cats.

Provided herein are methods of treating IgA nephropathy, comprising administering a therapeutically effective amount of atrasentan, or a pharmaceutically acceptable salt thereof, to a subject in need thereof Also provided herein are methods of decreasing renal inflammation and / or fibrosis, decreasing the occurrence of hematuria, stabilizing eGFR. decreasing the number of IgA-nephropathy associated disease flares, delaying the onset of ESRD, decreasing proteinuria, and decreasing fatigue in a subject having IgA nephropathy, comprising administering a therapeutically effective amount of atrasentan, or a pharmaceutically acceptable salt thereof, to the subject. In some embodiments, the subject has not been previously diagnosed with one or more of diabetic nephropathy, HIV / AIDS, HIV-related nephropathy, prostate cancer, or acute kidney failure

The present application relates to a synbiotic composition for use in the amelioration, treatment, reductions of symptoms of a neuropsychiatric disorder and / or the reduction of side effects of a pharmacological treatment of a neuropsychiatric disorder, wherein the synbiotic composition comprises at least two bacterial strains chosen from the group consisting of Lactobacillus plantarum, Lactobacillus paracasei, Pediococcus pentosaceus, Leuconostoc mesenteroides, and Bifidobacterium breve; and at least one dietary fibers chosen from the group consisting of inulin, pectin, beta-glucan, resistant starch, a galacto-oligosaccharide, an isomalto-oligosaccharide and a rice fiber.

The present disclosure relates to collagen binding modification engineering of anti-inflammatory agents using collagen binding peptides (CBP) and vWF A3 to achieve targeted therapy of inflammatory diseases. Accordingly, embodiments of the present disclosure relate to compositions comprising an anti-inflammatory agent operably linked to an extracellular matrix (ECM) affinity peptide. Also disclosed are cytokines and anti-inflammatory agents, such as CD200, linked to serum proteins and / or ECM affinity peptides. Other aspects of the present disclosure relate to methods for treating an autoimmune or inflammatory disorder in a subject comprising administering to the subject a composition of the present disclosure.

The disclosure generally relates to ready to drink electrolyte solution. In particular the disclosure relates to a ready to drink electrolyte solution comprising isomaltulose, glucose, sodium ions, chromium ions and water; wherein the glucose concentration is greater than or equal to 0.9g / 100ml, and wherein the theoretical glycemic index of the solution is equal to or less than 55. The disclosure also relates to a method of manufacturing said ready to drink electrolyte solution. The disclosure also relates to a method of rehydrating a patient suffering from cancer, diabetes, acute or chronic illness, or a gastrointestinal disorder by using said ready to drink electrolyte solution.

Provided herein are compositions comprising a silicate, inositol, and optionally an amino acid, which have improved solubility and / or are crystalline. Also provided are methods of making the disclosed compositions, as well as methods of making beverages comprising the disclosed compositions.

Provided herein are methods of improving kidney function in a subject in need thereof.

Systems and methods for treating and / or preventing metabolic disorders and / or other medical conditions in patients (e.g., felines) are described, by administering a liquid pharmaceutical composition, preferably containing one or more SGLT-2 inhibitor compounds, to the patient via a delivery system including a syringe. The syringe is characterized by facilitating the simple, safe, and effective dosage of small volume measurements of the liquid pharmaceutical composition to the patient during administration.

The invention discloses application of glucoraphanin to preparation of a product for reducing biological accumulation of perfluorooctane sulfonate, and belongs to the technical field of biological medicine. The occurrence probability of the high PFOS level in the body of a participant frequently eating broccoli is confirmed to be remarkably reduced through population epidemiological experiments, and then the PFOS level in the body of the participant is confirmed to be remarkably reduced after glucoraphanin intervention through clinical RCT random control experiments. The glucoraphanin-intervened serum has the advantages that the glucoraphanin-intervened serum is used as a main body, the metabolic change of steroid, ceramide and bile acid in the glucoraphanin-intervened serum is confirmed to be closely related to the reduction of the PFOS level through lipidomics analysis, and finally, the glucoraphanin is confirmed to be capable of effectively reducing the PFOS in-vivo accumulation and improving the liver injury caused by the PFOS through animal experiments and an AI reverse targeting technology; and the glucoraphanin and the in-vivo metabolite sulforaphane thereof have relatively strong binding capacity with a liver-specific PXR receptor, so that a good technical foundation is laid for research and development of drugs for treating diseases related to PFOS accumulation.

Provided herein are pharmaceutical compositions comprising therapeutic agent (s) and functional excipients that can enable oral absorption of small molecules and / or large molecules. Also provided herein are methods of preparing the pharmaceutical composition and methods of using the same for treating various diseases or disorders such as type-2 diabetes, obesity, NASH, renal disease.

The present invention discloses a formulation of bioactive liposomal gummies and a process of preparation thereof. The formulation comprises a bioactive component, an encapsulating agent, a sweetening agent, a flavoring agent, a gelling agent, an acidity regulator, a coloring agent, a bulking agent, a texturing agent, a thickening agent, a cross-linking polymer and water. The invention discloses a method of preparation of bioactive liposome using nano-milling process subsequently high-pressure homogenization, followed by a spray drying process. The process results in formulating dried bioactive liposomal gummies that exhibit increased stability and bioavailability of the liposomes making it a suitable for drug delivery system for wide range of bioactive agents. The bioactive liposomal gummies exhibit pH and temperature stability along with being palatable.

The pharmacokinetic profile of the SGLT2 inhibitor bexagliflozin can be improved by formulating it as an extended-release tablet. Compared to standard immediate-release dosage forms, these tablets achieve a shorter peak plasma concentration C while maintaining therapeutic plasma concentrations for the desired period. max This can be used, for example, to administer lower doses while still providing the same pharmacological effect.

Compounds that modulate the conversion of AMP to adenosine by 5′-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and / or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5′-nucleotidase, ecto is also provided.

The present disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in the treatment of infectious diseases, viral infections, and cancer, wherein the base of the nucleotide or nucleoside contains at least one thiol, thione, or thioether.

The present disclosure describes lipid nanoparticle (LNP) compositions and uses thereof, e.g. for treating ocular-related disorders or diseases.

The present disclosure relates to a 5'-modified nucleoside derivative and an oligonucleotide comprising same. Specifically, the oligonucleotide comprises at least one structure represented by formula (I), wherein each functional group is defined in the context of the present disclosure.

The present invention relates to a composition comprising regulators / modulators of T1R2 / T1R3, T1R1 / T1R3, CaSR and GPRC6A affecting body metabolism. Moreover, the composition can assists in promoting early satiety sensation and optimizing insulin section during and / or after meals.

The present disclosure provides human inhibin subunit beta E (INHBE) gene-targeting double stranded oligonucleotides, compositions, and methods of using the same, either alone or in combination with additional therapeutics, for preventing and / or treating various INHBE-related disorders, including maintenance of weight loss achieved. In some embodiments, the provided double stranded oligonucleotides comprise certain chemistry modifications, e.g., stereospecific internucleotidic linkage modifications, and have unexpected advantageous properties.

The present invention relates to a biocompatible, tissue adhesive, chitosan flowable dressing, optionally modified with catechol, and suitable for treating bleeding in a physiological environment, e.g., gastrointestinal tract, bladder (in particular in connection with the TURP procedure). The characteristics and structures of the chitosan dressing are provided. Methods of making and using the chitosan dressing are also provided.